Last reviewed · How we verify
NCT03939156: ELENA
Patients' Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer
trial testing Completion of questionnaires in Breast Cancer in 450 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | European Institute of Oncology |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 450 |
| Start date | 5 June 2018 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Completion of questionnaires
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Endocrine Breast Diseases — all drugs for Endocrine Breast Diseases →
Sponsor
European Institute of Oncology
Who can join
18 and older, female only, with Breast Cancer or Endocrine Breast Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Preference studies reveal how individuals trade-off the potential benefits, harms and inconveniences of a treatment by determining the minimum benefits they judge sufficient to make the treatment worthwhile. They are especially relevant to adjuvant therapies where individuals must weigh up modest survival benefits only realized in time by no recurrence of their cancer with side effects predominantly experienced whilst on the treatment. Previously it was reported, for example, that over 50% of women who had adjuvant chemotherapy for early breast cancer judged a 1% improvement in 5 year survival rates sufficient to make it worthwhile. Larger survival benefits were required for longer duration adjuvant hormonal therapy where over 50% of women required at least 5% improvement in 5 year survival rates to make it worthwhile.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03939156
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Completion of questionnaires
Trials testing the same drug.
- NCT04966091 — Working IVF Patients' Quality of Life · completed
- NCT06332976 — PrefeRences And ChemoTherapy In Breast Cancer patiEnts · unknown
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other European Institute of Oncology trials
Trials by the same sponsor.
- NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
- NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
- NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03939156 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
- Last refreshed: 28 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03939156.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing